The closing price of Moderna Inc (NASDAQ: MRNA) was $105.09 for the day, up 2.15% from the previous closing price of $102.88. In other words, the price has increased by $+2.21 from its previous closing price. On the day, 2058369 shares were traded. MRNA stock price reached its highest trading level at $105.22 during the session, while it also had its lowest trading level at $101.08.
Ratios:
Our analysis of MRNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.36 and its Current Ratio is at 3.42. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, HSBC Securities on February 26, 2024, Downgraded its rating to Reduce and sets its target price to $86 from $75 previously.
On January 02, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $142.
On November 29, 2023, Canaccord Genuity started tracking the stock assigning a Hold rating and target price of $82.Canaccord Genuity initiated its Hold rating on November 29, 2023, with a $82 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 03 ’24 when AFEYAN NOUBAR sold 15,000 shares for $101.68 per share. The transaction valued at 1,525,268 led to the insider holds 2,086,931 shares of the business.
AFEYAN NOUBAR sold 15,000 shares of MRNA for $1,635,864 on Mar 27 ’24. The Director now owns 2,101,931 shares after completing the transaction at $109.06 per share. On Mar 20 ’24, another insider, AFEYAN NOUBAR, who serves as the Director of the company, sold 15,000 shares for $102.39 each. As a result, the insider received 1,535,820 and left with 2,116,931 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 40.26B and an Enterprise Value of 32.89B. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.87 while its Price-to-Book (P/B) ratio in mrq is 2.90. Its current Enterprise Value per Revenue stands at 4.87 whereas that against EBITDA is -10.02.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $163.24, while it has fallen to a 52-week low of $62.55. The 50-Day Moving Average of the stock is 99.48, while the 200-Day Moving Average is calculated to be 99.71.
Shares Statistics:
MRNA traded an average of 3.98M shares per day over the past three months and 3.42M shares per day over the past ten days. A total of 382.00M shares are outstanding, with a floating share count of 336.23M. Insiders hold about 12.18% of the company’s shares, while institutions hold 65.82% stake in the company. Shares short for MRNA as of Mar 15, 2024 were 22.23M with a Short Ratio of 5.58, compared to 24.08M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.81% and a Short% of Float of 7.65%.
Earnings Estimates
The firm’s stock currently is rated by 14 analysts. On average, analysts expect EPS of -$3.18 for the current quarter, with a high estimate of -$1.79 and a low estimate of -$3.98, while EPS last year was $0.19. The consensus estimate for the next quarter is -$3.22, with high estimates of -$2.69 and low estimates of -$3.96.
Analysts are recommending an EPS of between -$5.37 and -$7.64 for the fiscal current year, implying an average EPS of -$6.64. EPS for the following year is -$4.78, with 22 analysts recommending between -$0.97 and -$7.
Revenue Estimates
A total of 22 analysts have provided revenue estimates for MRNA’s current fiscal year. The highest revenue estimate was $4.36B, while the lowest revenue estimate was $3.4B, resulting in an average revenue estimate of $3.86B. In the same quarter a year ago, actual revenue was $6.31B, down -38.80% from the average estimate. Based on 21 analysts’ estimates, the company’s revenue will be $4.31B in the next fiscal year. The high estimate is $5.42B and the low estimate is $2.98B. The average revenue growth estimate for next year is up 11.60% from the average revenue estimate for this year.
